🔎 Trials Near Me

Hjem › Akut myeloid leukæmi › Rhode Island › Providence

Akut myeloid leukæmi kliniske forsøg i Providence, RI

10 studier for Akut myeloid leukæmi søger deltagere på steder i og omkring Providence (inden for ca. 30 miles). Åbn et studie for at se, hvem der kan deltage, og hvordan man kontakter studieteamet.

Officiel studietekst (engelsk)

Rekrutterer til et studie her? Få det vist øverst på siden — $99 i 30 dage →

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

RekruttererFase 2
  • Rhode Island Hospital, Providence
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT05564390

Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation

RekruttererFase 3
  • Clinical Trial Site, Providence
Alder 12 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT07211958

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

RekruttererFase 2
  • Rhode Island Hospital, Providence
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT06317649

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

RekruttererFase 2
  • Rhode Island Hospital, Providence
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT06672146

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

RekruttererFase 2
  • Rhode Island Hospital, Providence
Alder 18 til 59 · Alle køn · Opdateret 22. sep. 2026 · NCT05554406

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

RekruttererFase 3
  • Rhode Island Hospital, Providence
6 Months – 21 Years · Alle køn · Opdateret 17. sep. 2026 · NCT04293562

L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML

RekruttererFase 2/3
  • University of Rhode Island, Providence
Alder 18 til 80 · Alle køn · Opdateret 5. aug. 2026 · NCT06788756

Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents

RekruttererFase 2
  • Lifespan Health System Rhode Island Hospital, Providence
Alder 18 og opefter · Alle køn · Opdateret 10. jul. 2026 · NCT05442216

Akut myeloid leukæmi forsøg i andre byer

Andre studier i Providence

Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.